首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1441309

全球緩釋性賦形劑市場規模、佔有率、成長分析（按產品類型、給藥途徑和技術）- 產業預測，2023-2030 年

Global Sustained Release Excipients Market Size, Share, Growth Analysis, By Product type(Gelatin, Polymers), By Route of Administration(Oral, Intramuscular), By Technology(Targeted Delivery, Microencapsulation) - Industry Forecast 2023-2030

出版日期: 2024年02月22日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球緩釋性賦形劑市場規模為12.6億美元，從2023年的13.7億美元成長到2031年的26億美元，在預測期間（2024-2031年）預計年複合成長率為8.4%。

全球緩釋性賦形劑市場穩步成長，預計未來將繼續擴大。緩釋性賦形劑是製劑的重要組成部分，目的是在較長時間內逐漸釋放活性成分，提高患者的依從性和治療結果。該市場受到多種因素的推動，例如慢性病的流行、對創新藥物輸送系統的需求不斷增加以及藥物研發投資的增加。此外，人口老化以及由此導致的長效藥物需求激增進一步推動了市場成長。緩釋性利用多種賦形劑，包括聚合物、脂質和水凝膠。乙基纖維素、羥丙基甲基纖維素（HPMC）和聚乳酸乙醇酸（PLGA）等聚合物因其生物相容性、控制釋放特性和配方的多功能性而特別引人注目。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東、非洲
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2021年）
主要市場參與者所採取的策略
關鍵成功策略
近期市集活動
主要企業市場佔有率（2021年）

主要企業簡介

Allergan PLC (Ireland)
AstraZeneca (UK)
GlaxoSmithKline PLC (UK)
Mayne Pharma Group Limited (Australia)
Mylan NV (US)
Novartis AG (Switzerland)
Pfizer Inc. (US)
Salix Pharmaceuticals (US)
Sun Pharmaceutical Industries Ltd (India)
Roche Holdings AG (Switzerland)
Sanofi (France)
Johnson & Johnson (US)
Eli Lilly and Company (US)
Merck & Co., Inc. (US)
Teva Pharmaceutical Industries Ltd (Israel)
AbbVie Inc. (US)
Bristol-Myers Squibb (US)
Gilead Sciences, Inc. (US)
Bayer AG (Germany)
Takeda Pharmaceutical Company Limited (Japan)

簡介目錄

Product Code: SQMIG35I2231

Global Sustained Release Excipients Market size was valued at USD 1.26 billion in 2022 and is poised to grow from USD 1.37 billion in 2023 to USD 2.60 billion by 2031, growing at a CAGR of 8.4% in the forecast period (2024-2031).

The global sustained release excipients market was experiencing steady growth and is expected to continue expanding in the coming years. Sustained release excipients are crucial components in drug formulations designed to release active ingredients gradually over an extended period, thereby improving patient compliance and therapeutic outcomes. The market is driven by several factors, including the rising prevalence of chronic diseases, increasing demand for innovative drug delivery systems, and growing investment in pharmaceutical research and development. Additionally, the aging population and the subsequent surge in demand for long-acting medications further fuel market growth. Various excipients are utilized in sustained release formulations, including polymers, lipids, and hydrogels, among others. Polymers such as ethylcellulose, hydroxypropyl methylcellulose (HPMC), and poly (lactic-co-glycolic acid) (PLGA) are particularly prominent due to their biocompatibility, controlled release properties, and versatility in formulation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sustained Release Excipients Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sustained Release Excipients Market Segmental Analysis

Based on product type the market is segmented as Gelatin, Polymers, Minerals, Sugars, and Others. On the basis of route of administration the market is segmented as Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Other Routes of Administration. Based on technology, it is segregated into Targeted Delivery, Microencapsulation, Wurster Technique, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Sustained Release Excipients Market

One key market driver propelling the growth of the sustained release excipients market is the rising geriatric population worldwide. With aging populations, there is a higher incidence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions, necessitating long-term medication regimens. Sustained release formulations offer advantages in terms of improved patient compliance, reduced side effects, and enhanced therapeutic outcomes by maintaining consistent drug levels in the body over an extended period. Consequently, pharmaceutical manufacturers are increasingly incorporating sustained release excipients into their formulations to cater to the needs of the aging population, thereby driving market expansion.

Restraints in the Global Sustained Release Excipients Market

However, despite the promising growth prospects, the sustained release excipients market faces certain restraints that may hinder its growth trajectory. One notable challenge is the stringent regulatory requirements governing the approval and commercialization of sustained release formulations. Regulatory agencies impose rigorous standards for the safety, efficacy, and quality of pharmaceutical products, including those utilizing sustained release technologies. Meeting these regulatory guidelines demands substantial investments in research, development, and manufacturing capabilities, which can pose barriers to entry for smaller players and startups. Moreover, delays in regulatory approvals can prolong the time to market, impacting product launch timelines and revenue generation potential for companies operating in this space.

Market Trends of the Global Sustained Release Excipients Market

In terms of trends, there is a growing emphasis on the development of innovative sustained release excipients to address evolving market needs and enhance product performance. Manufacturers are investing in advanced formulation technologies and excipient materials to achieve optimized drug release profiles, improved bioavailability, and enhanced stability of pharmaceutical formulations. Additionally, there is increasing adoption of multifunctional excipients capable of providing additional functionalities such as taste masking, moisture protection, and modified release kinetics. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and excipient suppliers are on the rise to leverage combined expertise and resources for product development and commercialization, thereby driving innovation and market growth in the sustained release excipients segment.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Sustained Release Excipients Market by Product type

Market Overview
Gelatin
Polymers
Minerals
Sugars
and Others

Global Sustained Release Excipients Market by Route of Administration

Market Overview
Oral
Intramuscular
Subcutaneous
Transdermal
Intravenous
and Other Routes of Administration

Global Sustained Release Excipients Market by Technology

Market Overview
Targeted Delivery
Microencapsulation
Wurster Technique
and Other Technologies

Global Sustained Release Excipients Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Allergan PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayne Pharma Group Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan NV (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Salix Pharmaceuticals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holdings AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments